Bristol-Myers Squibb Company (BMY)
Official siteHEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE
Market Cap: $129.66B
Last updated: Nov 17, 2026 at 11:05 AM ET
Bristol-Myers Squibb Company (BMY) Financials: Revenue, Profit and Cash Flow
Bristol-Myers Squibb Company reported revenue of $48.19B for the fiscal year ended Dec 31, 2025, down 0.2% from the year before. That year, net income was $7.05B with a net margin of 14.6%, operating cash flow was $14.16B and free cash flow was $12.85B. The quarter ended Sep 30, 2026 had revenue of $13.07B and net income of $2.16B.
Revenue and Margins
The operating margin was 20.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $19.43B, a compound annual rate of 10.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $48.19B | -0.2% | 63.4% | 20.8% | 14.6% |
| Dec 2024 | $48.30B | +7.3% | 43.4% | -15.5% | -18.5% |
| Dec 2023 | $45.01B | -2.5% | 74.2% | 16.2% | 17.9% |
| Dec 2022 | $46.16B | -0.5% | 76.3% | 18.0% | 13.7% |
| Dec 2021 | $46.38B | +9.1% | 76.1% | 15.9% | 15.1% |
| Dec 2020 | $42.52B | +62.6% | 72.3% | -21.6% | -21.2% |
| Dec 2019 | $26.14B | +15.9% | 69.1% | 22.6% | 13.2% |
| Dec 2018 | $22.56B | +8.6% | 71.3% | 22.7% | 21.9% |
| Dec 2017 | $20.78B | +6.9% | 71.1% | 16.6% | 4.7% |
| Dec 2016 | $19.43B | N/A | 74.4% | 23.0% | 23.2% |
Income Statement
In the fiscal year ended Dec 2025, net income turned positive after a loss the year before. In the quarter ended Sep 2026, net income fell 1.4% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B | $42.52B | $26.14B | $22.56B | $20.78B | $19.43B |
| Cost of revenue | $17.66B | $27.34B | $11.61B | $10.95B | $11.10B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B |
| Gross profit | $30.54B | $20.96B | $33.40B | $35.21B | $35.29B | $30.75B | $18.07B | $16.09B | $14.76B | $14.46B |
| Research and development | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B |
| Operating income | $10.00B | -$7.49B | $7.28B | $8.29B | $7.38B | -$9.19B | $5.91B | $5.11B | $3.45B | $4.47B |
| Net income | $7.05B | -$8.93B | $8.04B | $6.34B | $7.01B | -$8.99B | $3.46B | $4.95B | $975.00M | $4.51B |
| EBITDA | $13.34B | $1.22B | $18.20B | $17.99B | $18.78B | $3.51B | $8.41B | $6.79B | $6.16B | $6.47B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.07B | $12.97B | $11.49B | $12.50B | $12.22B | $12.27B | $11.20B | $12.34B | $11.89B | $12.20B | $11.87B | $11.48B |
| Gross profit | $7.37B | $9.25B | $7.97B | $7.01B | $8.15B | $7.39B | $7.98B | $7.50B | $8.67B | $8.80B | -$4.02B | $8.13B |
| Operating income | $2.84B | $4.03B | $3.27B | $1.42B | $3.01B | $2.27B | $3.31B | $480.00M | $1.91B | $1.56B | -$11.44B | $1.30B |
| Net income | $2.16B | $3.32B | $2.68B | $1.08B | $2.19B | $1.31B | $2.46B | $76.00M | $1.22B | $1.68B | -$11.91B | $1.76B |
Balance Sheet
As of Dec 2025, total debt of $45.11B exceeded cash and equivalents by $34.90B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B | $118.48B | $129.94B | $34.99B | $33.55B | $33.71B |
| Current assets | $29.39B | $29.78B | $31.77B | $27.27B | $33.26B | $30.19B | $29.35B | $17.72B | $14.85B | $13.70B |
| Cash and equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B | $14.55B | $12.35B | $6.91B | $5.42B | $4.24B |
| Total liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B | $80.60B | $78.25B | $20.86B | $21.70B | $17.36B |
| Short-term debt | $2.26B | $2.05B | $3.12B | $4.26B | $4.95B | $2.34B | $3.35B | $1.70B | $987.00M | $992.00M |
| Long-term debt | $42.85B | $47.60B | $36.65B | $35.06B | $39.60B | $48.34B | $43.39B | $5.65B | $6.97B | $5.72B |
| Shareholder equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B | $37.82B | $51.60B | $14.03B | $11.74B | $16.18B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $88.77B | $87.63B | $86.48B | $90.04B | $96.89B | $94.68B | $92.43B | $92.60B | $93.67B | $94.65B | $99.03B | $95.16B |
| Total liabilities | $65.37B | $65.31B | $66.37B | $71.53B | $78.29B | $77.19B | $74.98B | $76.22B | $76.47B | $77.58B | $82.48B | $65.67B |
| Cash and equivalents | $9.57B | $8.72B | $9.57B | $10.21B | $15.73B | $12.60B | $10.88B | $10.35B | $7.89B | $6.29B | $9.33B | $11.46B |
| Shareholder equity | $23.40B | $22.32B | $20.07B | $18.47B | $18.55B | $17.43B | $17.39B | $16.34B | $17.14B | $17.02B | $16.49B | $29.43B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 90.7% of operating cash flow. Dividends came to 39.2% of it, with no share repurchases.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B | $14.05B | $8.21B | $7.07B | $5.28B | $3.06B |
| Capital expenditures | $1.31B | $1.25B | $1.21B | $1.12B | $973.00M | $753.00M | $836.00M | $951.00M | $1.05B | $1.22B |
| Free cash flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B | $13.30B | $7.37B | $6.12B | $4.22B | $1.84B |
| Dividends paid | $5.04B | $4.86B | $4.74B | $4.63B | $4.40B | $4.08B | $2.68B | $2.61B | $2.58B | $2.55B |
| Share repurchases | $0 | $0 | $5.16B | $8.00B | $6.29B | $1.55B | $7.30B | $320.00M | $2.47B | $231.00M |
| Investing cash flow | -$4.13B | -$21.35B | -$2.29B | -$1.06B | -$538.00M | -$10.86B | -$9.91B | -$2.00B | -$66.00M | $1.48B |
| Financing cash flow | -$10.35B | $5.13B | -$9.42B | -$16.96B | -$16.22B | -$1.15B | $7.62B | -$3.54B | -$4.08B | -$2.65B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $4.18B | $3.39B | $1.10B | $1.97B | $6.31B | $3.92B | $1.95B | $4.44B | $5.59B | $2.33B | $2.83B | $4.25B |
| Capital expenditures | $344.00M | $305.00M | $347.00M | $370.00M | $320.00M | $361.00M | $260.00M | $378.00M | $324.00M | $262.00M | $284.00M | $330.00M |
| Free cash flow | $3.84B | $3.09B | $757.00M | $1.60B | $5.99B | $3.56B | $1.69B | $4.06B | $5.27B | $2.06B | $2.55B | $3.92B |
Frequently Asked Questions About BMY
What is Bristol-Myers Squibb Company's annual revenue?
Bristol-Myers Squibb Company reported revenue of $48.19B for the fiscal year ended Dec 31, 2025.
How fast is Bristol-Myers Squibb Company's revenue growing?
Revenue was down 0.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 1.4%.
Is Bristol-Myers Squibb Company profitable?
Yes. Bristol-Myers Squibb Company reported net income of $7.05B for the fiscal year ended Dec 31, 2025, with a net margin of 14.6%.
How much free cash flow does BMY generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $14.16B minus capital expenditures of $1.31B produced free cash flow of $12.85B.
How much debt does Bristol-Myers Squibb Company have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $42.85B, short-term debt of $2.26B and cash and equivalents of $10.21B.
BMY pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts